Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies

NCT04241835 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT04241835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04241835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies
Lead sponsor
Epizyme, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 15, 2020
Completion date
March 12, 2025
Enrollment
18 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumor, hepatic impairment